The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2019
Filed:
May. 22, 2017
Applicant:
Immunomedics, Inc., Morris Plains, NJ (US);
Inventors:
David M. Goldenberg, Mendham, NJ (US);
William A. Wegener, Broomall, PA (US);
Assignee:
Immunomedics, Inc., Morris Plains, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 51/08 (2006.01); B82Y 5/00 (2011.01); C07K 16/06 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 39/39558 (2013.01); A61K 39/39591 (2013.01); A61K 45/06 (2013.01); A61K 47/6879 (2017.08); A61K 47/6897 (2017.08); A61K 51/088 (2013.01); B82Y 5/00 (2013.01); C07K 16/065 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/2851 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01);
Abstract
Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.